What is the fair value of Aldeyra The (NASDAQ-ALDX) stock?

The current fair value estimate for Aldeyra The (NASDAQ-ALDX) is $1.23. This implies an estimated downside of 9.5% versus the current market price.

Is Aldeyra The (NASDAQ-ALDX) undervalued or overvalued?

Based on the current fair value estimate, the stock appears overvalued, with estimated downside of 9.5% versus the current market price.

What is the analyst price target for NASDAQ-ALDX stock?

The available analyst price target for Aldeyra The (NASDAQ-ALDX) is $6.60. The analyst target implies estimated upside of 385.3%.

How is the financial health of Aldeyra The?

The current financial health read for Aldeyra The (NASDAQ-ALDX) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

When is Aldeyra The's next earnings date?

The next earnings date currently listed for Aldeyra The (NASDAQ-ALDX) is November 12, 2026.

Does Aldeyra The (NASDAQ-ALDX) pay dividends?

The latest available data indicates no current dividend yield for Aldeyra The (NASDAQ-ALDX).

What is the market capitalization of Aldeyra The?

The current market capitalization listed for Aldeyra The is 82.044 M.

What is the enterprise value of Aldeyra The?

The current enterprise value listed for Aldeyra The is 37.705 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

What is the ticker symbol for Aldeyra The?

The ticker symbol for Aldeyra The is NASDAQ-ALDX, and the stock is listed on NASDAQ.

Where is Aldeyra The (NASDAQ-ALDX) listed?

Aldeyra The (NASDAQ-ALDX) is listed on NASDAQ.

What is the debt-to-total-capital ratio for Aldeyra The?

The current debt-to-total-capital ratio listed for Aldeyra The is 0.2%, which helps investors evaluate the company’s financing structure and leverage profile.

What is the free float for Aldeyra The?

The free float listed for Aldeyra The is 81.1%. Free float helps investors understand how much of the share base is available for public trading.

Aldeyra The (ALDX) Fair Value & Stock Analysis

Aldeyra The (ALDX)

Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering and developing therapies for immune-mediated diseases. Its clinical pipeline is led by reproxalap, a reactive aldehyde species (RASP) modulator being evaluated in Phase III trials for dry eye disease and allergic conjunctivitis. The company also is developing ADX-2191, a dihydrofolate reductase inhibitor under study for primary vitreoretinal lymphoma and retinitis pigmentosa. Another program, ADX-629, is an orally administered RASP modulator in Phase 2 trials for COVID-19, atopic asthma, psoriasis, and alcohol intoxication. Aldeyra also maintains preclinical RASP platforms, including ADX 248, ADX 246, and additional novel modulators. Founded in 2004 and formerly known as Aldexa Therapeutics, the company adopted its current name in March 2014 and is based in Lexington, Massachusetts.

Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.

Ticker	Fair Value	Fair Value Upside/Downside	Fair Value Rating	Analyst Price Target	Analyst Target Upside/Downside	Analyst Target Rating	Overall Financial Health	Dividend Yield	Next Earnings Date	Price-to-Book Ratio	Market Cap	Enterprise Value	Total Debt / Total Capital	Free Float / Shares Outstanding	Altman Z-Score	Free Cash Flow / Net Income
NASDAQ-ALDX	$1.23	-9.5% Downside	Fair	$6.60	385.3% Upside	Bargain	Fair	0.0%	November 12, 2026	2.2x	82.044 M	37.705 M	0.2%	81.1%	-10.1	95.6%